Publications by authors named "Seock-Ah Im"

100Publications

HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor.

Ann Clin Transl Neurol 2020 11 8;7(11):2243-2250. Epub 2020 Oct 8.

Department of Neurology, Seoul National University Hospital, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/acn3.51213DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664281PMC
November 2020

Association of Insulin, Metformin, and Statin with Mortality in Breast Cancer Patients.

Cancer Res Treat 2020 Sep 23. Epub 2020 Sep 23.

Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2020.430DOI Listing
September 2020

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.

Breast Cancer Res Treat 2020 Dec 28;184(3):743-753. Epub 2020 Aug 28.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-020-05891-0DOI Listing
December 2020

Homologous repair deficiency score for identifying breast cancers with defective DNA damage response.

Sci Rep 2020 07 27;10(1):12506. Epub 2020 Jul 27.

Biomedical Research Institute, Seoul National University Hospital, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-020-68176-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7385153PMC
July 2020

Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.

Cancer Res Treat 2020 Oct 11;52(4):1178-1187. Epub 2020 Jun 11.

Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2020.313DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577821PMC
October 2020

Effect of Timing of Gonadotropin-Releasing Hormone Agonist Administration for Ovarian Protection in Patients with Breast Cancer.

J Breast Cancer 2020 Jun 11;23(3):268-278. Epub 2020 May 11.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4048/jbc.2020.23.e33DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7311369PMC
June 2020

Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients.

J Bone Miner Res 2020 May 7. Epub 2020 May 7.

Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.4041DOI Listing
May 2020

PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.

Cancers (Basel) 2020 Feb 8;12(2). Epub 2020 Feb 8.

Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12020394DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072193PMC
February 2020

TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy.

Cancers (Basel) 2020 Feb 3;12(2). Epub 2020 Feb 3.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul 03080, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers12020334DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072281PMC
February 2020

Clinicopathological Features of Patients with the BRCA1 c.5339T>C (p.Leu1780Pro) Variant.

Cancer Res Treat 2020 Jul 28;52(3):680-688. Epub 2020 Jan 28.

Department of Surgery, Breast Care Center, Daerim St. Mary's Hospital, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4143/crt.2019.351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7373877PMC
July 2020

The effect of perceived social support on chemotherapy-related symptoms in patients with breast cancer: A prospective observational study.

J Psychosom Res 2020 03 20;130:109911. Epub 2019 Dec 20.

Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea; Department of Psychiatry and Behavioral Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpsychores.2019.109911DOI Listing
March 2020

Amenorrhea and Menopause in Patients with Breast Cancer after Chemotherapy.

J Breast Cancer 2019 Dec 13;22(4):624-634. Epub 2019 Nov 13.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4048/jbc.2019.22.e53DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6933038PMC
December 2019

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2020 02 11;382(6):514-524. Epub 2019 Dec 11.

From the David Geffen School of Medicine at UCLA, Los Angeles (D.J.S.); Multidisciplinary Breast Center, Universitair Ziekenhuis Leuven, Leuven (P.N.), and Centre Hospitalier Universitaire Liège and Liege University, Liege (G.J.) - all in Belgium; the British Columbia Cancer Agency, Vancouver, Canada (S.C.); University Hospital Erlangen, Comprehensive Cancer Center Erlangen-European Metropolitan Region of Nuremberg, and Department of Gynecology and Obstetrics, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen (P.A.F.), and the Practice for Hematology and Internal Oncology, Velbert (A.N.) - all in Germany; Istituto Nazionale Tumori Fondazione G. Pascale, Naples (M.D.L.), and Fondazione IRCCS Istituto Nazionale dei Tumori, Milan (G.V.B.) - both in Italy; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Masaryk Memorial Cancer Institute, Brno, Czech Republic (K.P.); New York University Langone Health, New York (F.J.E.); Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid (M.M.), and Hospital Universitario Virgen Macarena, Department of Medicine, Universidad de Sevilla, Seville (L.D.C.-M.) - both in Spain; Netherlands Cancer Institute-Borstkanker Onderzoek Groep Study Center, Amsterdam (G.S.S.); Highlands Oncology Group, Fayetteville, AR (J.T.B.); Institut Régional du Cancer, Strasbourg, France (X.P.); Novartis Pharmaceuticals, East Hanover, NJ (M.S., A.C., K.R.-L.); and Novartis Pharma, Basel, Switzerland (Y.W., T.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1911149DOI Listing
February 2020

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

N Engl J Med 2020 02 11;382(7):610-621. Epub 2019 Dec 11.

From Memorial Sloan Kettering Cancer Center, New York (S.M.); Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona (C.S., J.C.), and IOB Institute of Oncology, Quiron Group, Barcelona and Madrid (J.C.); Kanagawa Cancer Center, Yokohama (T.Y.), National Cancer Center Hospital (K.T.), the Cancer Institute Hospital of the Japanese Foundation for Cancer Research (Y.I.), and the Advanced Cancer Translational Research Institute, Showa University (J.T.), Tokyo, Aichi Cancer Center Hospital, Nagoya (H.I.), Kindai University Faculty of Medicine, Osaka (J.T.), Shikoku Cancer Center, Matsuyama (K.A.), and the National Hospital Organization Kyushu Cancer Center, Fukuoka (E.T.) - all in Japan; Samsung Medical Center (Y.H.P.), Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Yonsei Cancer Center, Yonsei University Health System (J. Sohn), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), Seoul, and the National Cancer Center, Gyeonggi (K.S.L.) - all in South Korea; Institut Gustave Roussy, Université Paris-Sud, Villejuif (F.A.), and Centre Eugène Marquis, Rennes (C.P.) - both in France; the US Oncology Network, Virginia Cancer Specialists, Arlington (N.D.); the University of California, Los Angeles-Jonsson Comprehensive Cancer Center, Los Angeles (S.A.H.); Daiichi Sankyo, Basking Ridge, NJ (C.L., S.C., L.Z., J. Shahidi, A.Y.); and the Dana-Farber Cancer Institute, Boston (I.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1914510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458671PMC
February 2020

The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab.

Biomolecules 2019 10 19;9(10). Epub 2019 Oct 19.

Department of Biochemistry and Molecular Biology, Seoul National University College of Medicine, Seoul National University, Seoul 03080, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/biom9100629DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843359PMC
October 2019

Ribociclib and Endocrine Therapy in Breast Cancer. Reply.

N Engl J Med 2019 10;381(16):1592-1593

University of Texas M.D. Anderson Cancer Center, Houston, TX

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMc1911188DOI Listing
October 2019

Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response.

Int J Radiat Biol 2019 12 26;95(12):1640-1647. Epub 2019 Sep 26.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09553002.2019.1665212DOI Listing
December 2019

Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer.

Clin Breast Cancer 2020 04 21;20(2):98-107.e1. Epub 2019 Aug 21.

Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2019.07.010DOI Listing
April 2020

Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11).

Breast Cancer Res Treat 2019 Nov 12;178(2):367-377. Epub 2019 Aug 12.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05400-yDOI Listing
November 2019

Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea.

Chin Clin Oncol 2019 Jun;8(3):27

Department of Internal Medicine, Clinical Trials Center, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2019.06.05DOI Listing
June 2019

Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.

Anticancer Drugs 2019 09;30(8):866-872

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000808DOI Listing
September 2019

Prognostic Impact of Pregnancy in Korean Patients with Breast Cancer.

Oncologist 2019 12 2;24(12):e1268-e1276. Epub 2019 Jul 2.

Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2019-0167DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6975968PMC
December 2019

Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer.

Support Care Cancer 2020 Mar 1;28(3):1351-1358. Epub 2019 Jul 1.

Department of Psychiatry and Behavioral Sciences, Seoul National University College of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04949-0DOI Listing
March 2020

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

N Engl J Med 2019 07 4;381(4):307-316. Epub 2019 Jun 4.

From Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine (S.-A.I.), the Yonsei Cancer Center, Yonsei University Health System (J.S.), and the Asan Medical Center, University of Ulsan College of Medicine (K.-H.J.), Seoul, and the Center for Breast Cancer, National Cancer Center, Gyeonggi-do (K.-S.L.) - all in South Korea; National Taiwan University Hospital, Taipei, Taiwan (Y.-S.L.); Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston (A.B.); the Breast Center, Department of Obstetrics and Gynecology, Ludwig-Maximilians-University Munich, Munich, Germany (N.H.); the Division of Medical Senology, Istituto Europeo di Oncologia, Milan (M.C.); Hospital de Caridade de Ijuí, CACON, Ijuí, Brazil (F.F.); the Organisation for Oncology and Translational Research, Hong Kong (L.C.); Centro Oncológico Estatal, Instituto de Seguridad Social del Estado de México y Municipios, Toluca, Mexico (S.C.-G.); Institut Català d'Oncologia, Hospital de Sant Joan Despí Moisès Broggi, Barcelona (R.V.-V.); Novartis Pharmaceuticals, East Hanover, NJ (A.C., K.R.-L., T.T.); Novartis, Basel, Switzerland (G.H., I.G.); the UCLA Jonsson Comprehensive Cancer Center, Los Angeles (S.H.); and the University of Texas M.D. Anderson Cancer Center, Houston (D.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1903765DOI Listing
July 2019

Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.

Breast Cancer Res Treat 2019 Jul 26;176(2):453-460. Epub 2019 Apr 26.

Department of Preventive Medicine, The Catholic University of Korea, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05249-1DOI Listing
July 2019

Prognostic effects of abnormal DNA damage response protein expression in breast cancer.

Breast Cancer Res Treat 2019 May 22;175(1):117-127. Epub 2019 Jan 22.

Translational Medicine, Seoul National University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-019-05128-9DOI Listing
May 2019

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

N Engl J Med 2018 11 20;379(22):2108-2121. Epub 2018 Oct 20.

From the Barts Cancer Institute, Queen Mary University of London, London (P.S.); Perlmutter Cancer Center, New York University School of Medicine, New York (S.A.); the Department of Medicine, University of California, San Francisco, San Francisco (H.S.R.), and Genentech, South San Francisco (L.M., S.Y.C., R.F.) - both in California; University Hospital Heidelberg, Heidelberg, Germany (A.S.); Centro de Pesquisa em Oncologia, Hospital São Lucas, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre (C.H.B.), and the University of São Paulo, São Paulo (R.H.) - both in Brazil; Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); the Department of Medical Oncology, Institut Curie, Paris (V.D.); Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Florida Cancer Specialists and Research Institute, New Port Richey (G.S.W.); Roche, Basel, Switzerland (V.H., A.H.); Dana-Farber Cancer Institute, Boston (E.P.W.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S.L.); and the Bloomberg-Kimmel Institute for Cancer Immunotherapy at Johns Hopkins, Baltimore (L.A.E.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1809615
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1809615DOI Listing
November 2018

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

N Engl J Med 2018 Nov 20;379(20):1926-1936. Epub 2018 Oct 20.

From the Institute of Cancer Research and Royal Marsden Hospital, London (N.C.T.); David Geffen School of Medicine at University of California, Los Angeles, Santa Monica (D.J.S.), and Pfizer Oncology, San Diego (X.H.) - both in California; National Cancer Center, Goyang-si, Gyeonggi-do (J.R.), and Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul (S.-A.I.) - both in South Korea; Dnipropetrovsk Medical Academy, City Multiple-Discipline Clinical Hospital 4, Dnipropetrovsk, Ukraine (I.B.); National Hospital Organization Osaka National Hospital, Osaka (N.M.), and Aichi Cancer Center Hospital, Nagoya (H.I.) - both in Japan; Istituto Europeo di Oncologia (M. Colleoni) and Pfizer Oncology (C.G.) - both in Milan; Abramson Cancer Center, University of Pennsylvania, Philadelphia (A.D.), and Pfizer Oncology, Collegeville (C.H.B.) - both in Pennsylvania; Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada (S.V.); Brustzentrum der Universität München, Munich (N.H.), and the German Breast Group, Neu-Isenburg (S. Loibl) - both in Germany; Institut Gustave Roussy, Villejuif, France (F.A.); Pfizer Oncology, Cambridge, MA (K.P.T.); and the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Feinberg School of Medicine, Chicago (M. Cristofanilli).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1810527
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1810527DOI Listing
November 2018

Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.

Breast Cancer Res Treat 2018 Dec 12;172(3):619-626. Epub 2018 Sep 12.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-018-4966-9DOI Listing
December 2018

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

J Clin Oncol 2018 08 3;36(24):2465-2472. Epub 2018 Jun 3.

Dennis J. Slamon, University of California Los Angeles Medical Center, Santa Monica, CA; Patrick Neven, Multidisciplinary Breast Centre, Universitair Ziekenhuis, Leuven; Guy Jerusalem, Centre Hospitalier Universitaire de Liege and Liege University, Liège, Belgium; Stephen Chia, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Peter A. Fasching, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen; Arnd Nusch, Practice for Hematology and Internal Oncology, Velbert, Germany; Michelino De Laurentiis, Istituto Nazionale Tumori "Fondazione G. Pascale," Naples; Giulia Val Bianchi, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy; Seock-Ah Im, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea; Katarina Petrakova, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Francisco J. Esteva, New York University Langone Health, New York, NY; Miguel Martín, Instituto de Investigacion Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid; Luis De la Cruz-Merino, Hospital Universitario Virgen Macarena, Seville, Spain; Gabe S. Sonke, Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, the Netherlands; J. Thaddeus Beck, Highlands Oncology Group, Fayetteville, AR; Xavier Pivot, Institut Régional du Cancer, Strasbourg, France; Gena Vidam, Karen Rodriguez Lorenc, Michelle Miller, and Tetiana Taran, Novartis Pharmaceuticals, East Hanover, NJ; and Yingbo Wang, Novartis Pharma, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.78.9909
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.78.9909DOI Listing
August 2018

Oncologic Safety of Gonadotropin-Releasing Hormone Agonist for Ovarian Function Protection During Breast Cancer Chemotherapy.

Clin Breast Cancer 2018 10 19;18(5):e1165-e1172. Epub 2018 Apr 19.

Department of Surgery and Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clbc.2018.04.008DOI Listing
October 2018

Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.

Cancer Lett 2018 08 3;430:123-132. Epub 2018 May 3.

Cancer Research Institute, Seoul National University, South Korea; Biomedical Research Institute, Seoul National University Hospital, South Korea; Department of Internal Medicine, Seoul National University College of Medicine, South Korea; Translational Medicine, Seoul National University College of Medicine, Seoul, South Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2018.04.037DOI Listing
August 2018

Pre-treatment anxiety is associated with persistent chemotherapy-induced peripheral neuropathy in women treated with neoadjuvant chemotherapy for breast cancer.

J Psychosom Res 2018 05 21;108:14-19. Epub 2018 Feb 21.

Department of Psychiatry and Behavioral Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Neuropsychiatry, Seoul National University Hospital, Seoul, Republic of Korea. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jpsychores.2018.02.012DOI Listing
May 2018

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma.

BMC Cancer 2018 03 5;18(1):252. Epub 2018 Mar 5.

Department of Internal Medicine, Seoul National University Hospital, 101 Daehang-ro, Jongno-gu, Seoul, 110-744, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-018-4039-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838934PMC
March 2018

A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER/HER2 Advanced Breast Cancer.

Clin Cancer Res 2018 08 13;24(15):3510-3518. Epub 2018 Feb 13.

Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-17-3102DOI Listing
August 2018

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

J Clin Oncol 2018 04 26;36(10):968-974. Epub 2018 Jan 26.

Xavier Pivot, University Hospital Jean Minjoz, Institut National de la Santé et de la Recherche Médicale 1098, Besançon, France; Igor Bondarenko, State Institution Dnipropetrovsk Medical, Academy of the Ministry of Health of Ukraine, Communal Institution Dnipropetrovsk City Multifield Clinical Hospital No. 4 of Dnipropetrovsk Regional Council, Dnipropetrovsk; Yuriy Vinnyk, Communal Healthcare Institution Kharkiv, Regional Clinical Oncological Center, Kharkiv; Yaroslav Shparyk, Lviv State Oncological Regional Treatment and Diagnostic Center, Lviv, Ukraine; Zbigniew Nowecki, Centrum Onkologii-Instytutim. M. Sklodowskiej Curie; Tomasz Sarosiek, Magodent, Warsaw; Marek Z. Wojtukiewicz, Comprehensive Cancer Center, Medical University, Bialystok, Poland; Mikhail Dvorkin, BHI of Omsk Region, Clinical Oncology Dispensary, Omsk; Ekaterina Trishkina, SBHI Leningrad Regional Oncology Dispensary; Vladimir Moiseyenko, SBHI Saint Petersburg Scientific and Practical Center of Specialized Methods of Medical Help; Vladimir Semiglazov, FSI Scientific and Research Institution of Oncology n.a. N.N. Petrov of Ministry of Healthcare and SD of RF, St Petersburg, Russia; Jin-Hee Ahn, Asan Medical Center; Seock-Ah Im, Seoul National University Hospital, Seoul; Sujeong Song and Jaeyun Lim, Samsung Bioepis, Incheon, Republic of Korea; Sanjoy Chatterjee, Tata Medical Centre, Kolkata, India; and Maximino Bello III, St Luke's Medical Center, Quezon City, Philippines.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.0126DOI Listing
April 2018

Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.

Breast Cancer 2018 May 4;25(3):370-374. Epub 2018 Jan 4.

National Centre for Tumour Diseases, Heidelberg and Department of Gynecologic Oncology, University Hospital, Heidelberg, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12282-017-0826-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5906517PMC
May 2018

Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study.

J Breast Cancer 2017 Dec 19;20(4):368-377. Epub 2017 Dec 19.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4048/jbc.2017.20.4.368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5743997PMC
December 2017

Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.

J Clin Oncol 2018 03 15;36(8):741-748. Epub 2017 Dec 15.

Stephen R.D. Johnston, The Royal Marsden NHS Foundation Trust, London; Lisa S. Williams, Novartis Pharmaceuticals UK Limited, Frimley, United Kingdom; Roberto Hegg, Centro de Referência da Saúde da Mulher; Sergio D. Simon, Hospital Israelita Albert Einstein, São Paulo, Brazil; Seock-Ah Im, Seoul National University College of Medicine, Seoul; In Hae Park, National Cancer Center, Gyeonggi-do, Korea; Olga Burdaeva, Regional Oncology Dispensary, Arkhangelsk; Sergei Tjulandin, N.N. Blokhin Russian Cancer Research Center, Moscow, Russia; Galina Kurteva, University Cancer Center Hospital, Sofia, Bulgaria; Michael F. Press, University of Southern California, Los Angeles, CA; Hiroji Iwata, Aichi Cancer Center Hospital, Aichi, Japan; Sarah Kenny, Severine Sarp, and Miguel A. Izquierdo, Novartis Pharma AG, Basel, Switzerland; and William J. Gradishar, Northwestern University, Chicago, IL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.74.7824
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.74.7824DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7444639PMC
March 2018

Skeletal muscle depletion predicts survival of patients with advanced biliary tract cancer undergoing palliative chemotherapy.

Oncotarget 2017 Oct 2;8(45):79441-79452. Epub 2017 Jun 2.

Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.18345DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668056PMC
October 2017

Integrated F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy.

Eur J Nucl Med Mol Imaging 2018 03 4;45(3):328-339. Epub 2017 Nov 4.

Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-017-3849-3DOI Listing
March 2018

The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies.

Cancer Treat Rev 2017 Dec 12;61:53-60. Epub 2017 Oct 12.

MD Anderson Cancer Center, University of Texas, 1515 Holcombe Blvd, Houston 77030, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.09.011DOI Listing
December 2017

EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release.

Oncotarget 2017 Sep 12;8(38):63901-63910. Epub 2017 Jul 12.

Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Bundang-gu, Seongnam, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.19194DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5609971PMC
September 2017

Human Epidermal Growth Factor Receptor 2 Expression in Unresectable Gastric Cancers: Relationship with CT Characteristics.

Korean J Radiol 2017 Sep-Oct;18(5):809-820. Epub 2017 Jul 17.

Department of Radiology, Seoul National University Hospital, Seoul 03080, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3348/kjr.2017.18.5.809DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5552464PMC
December 2017

PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients.

J Glob Oncol 2017 Aug 11;3(4):289-303. Epub 2017 Apr 11.

, Aichi Cancer Center Hospital, Nagoya; , National Hospital Organization, Osaka National Hospital, Osaka; , Saitama Cancer Center, Saitama; , Sagara Hospital, Kagoshima City; , Chiba Cancer Center, Chiba, Japan; , Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine; , Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul; , Seoul National University Bundang Hospital, Seongnam; , National Cancer Center, Goyang, Republic of Korea; and , Pfizer, La Jolla, CA; , , and , Pfizer, New York, NY; and , Pfizer, Collegeville, PA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JGO.2016.008318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560465PMC
August 2017

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.

N Engl J Med 2017 08 4;377(6):523-533. Epub 2017 Jun 4.

From the Memorial Sloan Kettering Cancer Center, New York (M.R.); Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea (S.-A.I.); Medical University of Gdańsk, Gdańsk, Poland (E.S.); National Cancer Center-Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing (B.X.), and the First Hospital of Jilin University, Changchun (W.L.) - both in China; Basser Center, University of Pennsylvania, Philadelphia (S.M.D.); National Hospital Organization, Osaka National Hospital, Osaka, Japan (N.M.); Institut Gustave Roussy, Villejuif, France (S.D.); Beth Israel Deaconess Medical Center, Dana-Farber Harvard Cancer Center, Boston (N.T.); Christie Hospital NHS Foundation Trust and Faculty of Biology, Medicine and Health, University of Manchester, Manchester (A.A.), and AstraZeneca, Macclesfield (S.R.) - both in the United Kingdom; AstraZeneca, Gaithersburg, MD (W.W., C.G.); and University of Padua and Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico, Padua, Italy (P.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1706450DOI Listing
August 2017

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.

N Engl J Med 2017 06;376(22):2147-2159

From the National Hospital Organization Osaka National Hospital, Osaka (N.M.), Hiroshima City Hiroshima Citizens Hospital, Hiroshima (S. Ohtani), Kyoto Prefectural University of Medicine (I.Y.), and Graduate School of Medicine, Kyoto University (M.T.), Kyoto, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital (K.K.), and Chuo University (Y.O.), Tokyo, Gunma Prefectural Cancer Center, Ota (Y.Y.), National Hospital Organization Kyushu Cancer Center, Fukuoka (S. Ohno), Hyogo Cancer Center, Akashi (S.T.), National Hospital Organization Shikoku Cancer Center, Matsuyama (K.A.), Aichi Cancer Center Hospital, Nagoya (H.I.), and Tohoku University, Sendai (H.S.) - all in Japan; and Yeungnam University Hospital, Daegu (S.-J.L.), Samsung Medical Center, Sungkyunkwan University School of Medicine (Y.-H.I.), Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine (S.-A.I.), Severance Hospital (B.-W.P.) and Gangnam Severance Hospital (J.J.), Yonsei University College of Medicine, Asan Medical Center, University of Ulsan College of Medicine (S.-B.K.), Korea University Guro Hospital (A.K.), and Korea University Anam Hospital (K.-H.P.), Seoul, and National Cancer Center, Goyang-si (E.-S.L.) - all in South Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1612645DOI Listing
June 2017

Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Who Experienced Disease Progression During or After Trastuzumab-Based Therapy.

J Clin Oncol 2017 Sep 24;35(26):3030-3038. Epub 2017 Apr 24.

Ander Urruticoechea, Onkologikoa Foundation, San Sebastián; Ander Urruticoechea, Catalan Institute of Oncology-IDIBELL, L'Hospitalet de Llobregat, GEICAM; Montserrat Muñoz, Translational Genomics and Targeted Therapeutics in Solid Tumors and Hospital Clínic, Barcelona, GEICAM; Antonio Carlos Sánchez Ruiz, Hospital Universitario Puerta de Hierro, Madrid, Spain; Mohammed Rizwanullah, Beatson West of Scotland Cancer Centre, Glasgow; Hannah Douthwaite and Sarah Heeson, Roche, Welwyn Garden City, United Kingdom; Seock-Ah Im, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; István Láng, National Institute of Oncology, Budapest, Hungary; Gianluca Tomasello, ASST di Cremona - Ospedale di Cremona, Cremona, Italy; Tanja Badovinac Crnjevic, F Hoffmann-La Roche, Basel, Switzerland; and Jennifer Eng-Wong, Genentech, South San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.6267DOI Listing
September 2017